CY1108175T1 - ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR - Google Patents

ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR

Info

Publication number
CY1108175T1
CY1108175T1 CY20081100700T CY081100700T CY1108175T1 CY 1108175 T1 CY1108175 T1 CY 1108175T1 CY 20081100700 T CY20081100700 T CY 20081100700T CY 081100700 T CY081100700 T CY 081100700T CY 1108175 T1 CY1108175 T1 CY 1108175T1
Authority
CY
Cyprus
Prior art keywords
dcr3
tnfr
dcr3 polypeptide
homologue
tnfr homologue
Prior art date
Application number
CY20081100700T
Other languages
English (en)
Inventor
Avi J Ashkenazi
David Botstein
Kelly H Dodge
Austin L Gurney
Kyung Jin Kim
David A Lawrence
Robert Pitti
Margaret A Roy
Daniel B Tumas
William I Wood
Audrey Goddard
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of CY1108175T1 publication Critical patent/CY1108175T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Polymerization Catalysts (AREA)

Abstract

Παρέχεται ομόλογο TNFR, που ταυτοποιείται ως DcR3. Παρέχονται επίσης μόρια νουκλεϊκών οξέων που κωδικοποιούν DcR3, χιμαιρικά μόρια και αντισώματα εναντίον DcR3.
CY20081100700T 1997-09-18 2008-07-03 ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR CY1108175T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5928897P 1997-09-18 1997-09-18
US9464098P 1998-07-30 1998-07-30
EP98948386A EP1015587B1 (en) 1997-09-18 1998-09-18 DcR3 POLYPEPTIDE, A TNFR HOMOLOG

Publications (1)

Publication Number Publication Date
CY1108175T1 true CY1108175T1 (el) 2014-02-12

Family

ID=26738582

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100700T CY1108175T1 (el) 1997-09-18 2008-07-03 ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR

Country Status (13)

Country Link
US (5) US6764679B2 (el)
EP (1) EP1015587B1 (el)
JP (2) JP4303883B2 (el)
AT (1) ATE393222T1 (el)
AU (2) AU762959B2 (el)
CA (1) CA2303225C (el)
CY (1) CY1108175T1 (el)
DE (1) DE69839401T2 (el)
DK (1) DK1015587T3 (el)
ES (1) ES2306480T3 (el)
IL (3) IL134578A0 (el)
PT (1) PT1015587E (el)
WO (1) WO1999014330A1 (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US20040013664A1 (en) * 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
CN1247567A (zh) 1997-01-14 2000-03-15 人体基因组科学有限公司 肿瘤坏死因子受体6α和6β
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
IL134578A0 (en) 1997-09-18 2001-04-30 Genentech Inc DcR3 POLYPEPTIDE, A TNFR HOMOLOG
JP2002508168A (ja) * 1997-12-16 2002-03-19 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒト腫瘍壊死因子ｒ２様タンパク質
DE19809978A1 (de) * 1998-03-09 1999-09-16 Basf Ag Neuer Rezeptor aus der menschlichen Lunge
EA200001004A1 (ru) * 1998-03-30 2001-06-25 Эли Лилли Энд Компани ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ ЗРЕЛЫХ ПОЛИПЕПТИДОВ FLINT (mFLINT) ИЛИ OPG3, ЯВЛЯЮЩИХСЯ ЧЛЕНАМИ СУПЕРСЕМЕЙСТВА РЕЦЕПТОРОВ TNF
EP1140138A2 (en) * 1998-12-22 2001-10-10 Eli Lilly And Company Therapeutic applications of flint polypeptides
MXPA01007163A (es) * 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
AU774845B2 (en) * 1999-03-04 2004-07-08 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6alpha and 6beta
AU2495200A (en) * 1999-03-08 2000-09-28 Genentech Inc. Compositions and methods for the treatment of tumor
AU3739500A (en) * 1999-03-30 2000-10-16 Eli Lilly And Company Protease resistant flint analogs
US6835814B1 (en) 1999-03-30 2004-12-28 Eli Lilly And Company Protease resistant flint analogs
US6965012B1 (en) 1999-03-30 2005-11-15 Eli Lilly And Company Flint polypeptide analogs
JP2002539828A (ja) * 1999-03-30 2002-11-26 イーライ・リリー・アンド・カンパニー Ｆｌｉｎｔポリペプチドアナログ
AU2215300A (en) * 1999-06-02 2000-12-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
AU783682B2 (en) 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
WO2001010908A1 (en) * 1999-08-04 2001-02-15 Amgen Inc. Ntr3, a member of the tnf-receptor supergene family
WO2001018055A1 (en) * 1999-09-10 2001-03-15 Eli Lilly And Company Flint analog compounds and formulations thereof
AU7053000A (en) * 1999-09-10 2001-04-10 Eli Lilly And Company Flint compounds and formulations thereof
AU1915201A (en) * 1999-12-07 2001-06-18 Eli Lilly And Company Improving stability of flint through o-linked glycosylation
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
EP1363657A2 (en) * 2000-05-08 2003-11-26 Biogen, Inc. Method for promoting neovascularization using a tweak agonist and an angiogenic factor
EP1322667A4 (en) * 2000-08-25 2004-08-18 Human Genome Sciences Inc TUMOR NECROSIS FACTOR RECEPTORS 6-ALPHA AND 6-BETA
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
JP2005506282A (ja) * 2001-02-01 2005-03-03 イーライ・リリー・アンド・カンパニー Ｆｌｉｎｔグリコフォーム
NZ548701A (en) 2002-04-09 2008-03-28 Biogen Idec Inc Methods for treating tweak-related conditions
US20030055221A1 (en) * 2002-05-07 2003-03-20 Jirong Lu Stability of flint through o-linked glycosylation
EP1447093A1 (en) * 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20090269345A1 (en) * 2005-12-23 2009-10-29 Rong Fan CLN248 Antibody Compositions and Methods of Use
PL2101877T3 (pl) 2006-12-28 2013-11-29 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Neutralizacja aktywności cd95 blokuje inwazję komórek glejaka in vivo
EP3470087A1 (en) 2009-02-13 2019-04-17 Immunomedics, Inc. Lyophilised compositions of immunoconjugates with an intracellularly-cleavable linkage
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
PT2874659T (pt) 2012-07-18 2016-09-19 Apogenix Ag Inibidores da via de sinalização de cd95 para tratamento de smd
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
KR20230078823A (ko) 2012-12-13 2023-06-02 이뮤노메딕스, 인코오포레이티드 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
AU2015219495B2 (en) 2014-02-21 2019-11-21 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
WO2016057398A1 (en) 2014-10-07 2016-04-14 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
BR112022004590A2 (pt) 2019-09-13 2022-06-14 Kyowa Kirin Co Ltd Variante dcr3
IL293350A (en) 2019-11-27 2022-07-01 Myst Therapeutics Llc A method for producing tumor-reactive t cells using modulatory substances
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
KR0154872B1 (ko) 1987-12-21 1998-10-15 로버트 에이. 아미테이지 발아하는 식물종자의 아크로박테리움 매개된 형질전환
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
DK0417563T3 (da) 1989-09-12 2000-11-06 Hoffmann La Roche TNF-bindende proteiner
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
CN1247567A (zh) * 1997-01-14 2000-03-15 人体基因组科学有限公司 肿瘤坏死因子受体6α和6β
PT1012274E (pt) 1997-01-28 2007-08-14 Craig A Rosen Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
WO1999004001A1 (en) 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
AU8767698A (en) 1997-08-06 1999-03-01 Procter & Gamble Company, The Novel orphan receptor
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
IL134578A0 (en) 1997-09-18 2001-04-30 Genentech Inc DcR3 POLYPEPTIDE, A TNFR HOMOLOG
WO1999026977A1 (en) 1997-11-24 1999-06-03 Biogen, Inc. Novel receptors opg-2
JP2002508168A (ja) 1997-12-16 2002-03-19 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒト腫瘍壊死因子ｒ２様タンパク質
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
DE19809978A1 (de) 1998-03-09 1999-09-16 Basf Ag Neuer Rezeptor aus der menschlichen Lunge
EA200001004A1 (ru) 1998-03-30 2001-06-25 Эли Лилли Энд Компани ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ ЗРЕЛЫХ ПОЛИПЕПТИДОВ FLINT (mFLINT) ИЛИ OPG3, ЯВЛЯЮЩИХСЯ ЧЛЕНАМИ СУПЕРСЕМЕЙСТВА РЕЦЕПТОРОВ TNF
KR100529270B1 (ko) 1998-12-01 2005-11-21 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
AU774845B2 (en) 1999-03-04 2004-07-08 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6alpha and 6beta
KR20010103046A (ko) 1999-03-08 2001-11-17 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
JP2002539828A (ja) 1999-03-30 2002-11-26 イーライ・リリー・アンド・カンパニー Ｆｌｉｎｔポリペプチドアナログ
AU3739500A (en) 1999-03-30 2000-10-16 Eli Lilly And Company Protease resistant flint analogs
WO2001010908A1 (en) 1999-08-04 2001-02-15 Amgen Inc. Ntr3, a member of the tnf-receptor supergene family
TW528801B (en) 2000-12-05 2003-04-21 Anawrahta Biotech Co Ltd Monoclonal antibodies for the detection of decoy receptor 3, hybridomas producing said antibodies and uses thereof
CN102786631B (zh) * 2012-08-16 2014-05-14 京东方科技集团股份有限公司 光敏性碱可溶性树脂、其制备方法及彩色光刻胶

Also Published As

Publication number Publication date
JP4303883B2 (ja) 2009-07-29
US20040175791A1 (en) 2004-09-09
US20100080793A1 (en) 2010-04-01
PT1015587E (pt) 2008-07-31
WO1999014330A8 (en) 1999-05-27
DE69839401T2 (de) 2009-05-07
IL134578A0 (en) 2001-04-30
JP5153679B2 (ja) 2013-02-27
JP2001516581A (ja) 2001-10-02
US20020061559A1 (en) 2002-05-23
CA2303225C (en) 2015-03-31
ES2306480T3 (es) 2008-11-01
JP2009159970A (ja) 2009-07-23
AU762959B2 (en) 2003-07-10
US6764679B2 (en) 2004-07-20
ATE393222T1 (de) 2008-05-15
EP1015587B1 (en) 2008-04-23
US20040014176A1 (en) 2004-01-22
IL134578A (en) 2010-06-16
IL193919A0 (en) 2009-05-04
DK1015587T3 (da) 2008-08-25
AU2003252913A1 (en) 2003-11-06
US20020065210A1 (en) 2002-05-30
CA2303225A1 (en) 1999-03-25
EP1015587A1 (en) 2000-07-05
WO1999014330A1 (en) 1999-03-25
DE69839401D1 (en) 2008-06-05
AU9497098A (en) 1999-04-05

Similar Documents

Publication Publication Date Title
CY1108175T1 (el) ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR
DK1860187T3 (da) Apo-2-receptor
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
DE69833784D1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
IL193886A0 (en) Antibodies that bind to ldcam sequences
ATE435912T1 (de) Homolog nl6 des tie rezeptor tyrosinekinase liganden
DE69840230D1 (de) Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DE69939982D1 (de) B7l-1 moleküle
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
DK1009817T3 (da) RTD-receptor
NO930428L (no) Proteinstrukturen til plantetoksingelonin
FI971276A (fi) Lerk-6:ksi nimetty sytokiini
SE9602822D0 (sv) New receptor
ZA978503B (en) Vertebrate smoothened proteins
ATE351909T1 (de) Neue peptidfragmente zur reinigung von proteinen
ATE408687T1 (de) Semaphorin polypeptide
ATE317896T1 (de) Polypeptide mit glucanotransferase aktivität und dafür kodierende nukleinsäuren
DK0487229T3 (da) DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet